Goa Therapeutics exits stealth to develop a 'Narcan for alcohol'
The startup aims to create a rapid anti-intoxication drug that works like naloxone does for opioids.
Goa Therapeutics, a new biotechnology company, has emerged from stealth with the goal of developing a drug that rapidly reverses alcohol intoxication. It describes its vision as a 'Narcan for alcohol,' pointing to naloxone as the model for an acute antidote.
The company calls the opportunity 'immeasurably huge' and frames the intended product as the 'greatest therapeutic of all time.' That framing suggests an emergency medicine meant to sober up someone who has consumed too much alcohol, rather than a treatment taken on a daily basis.
The launch announcement does not disclose specific drug candidates, preclinical data, or clinical plans. For now, the public picture is limited to the concept itself and the company's stated ambition.
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.